What is Apismart 2.5mg Apixaban Tablets?
Apismart 2.5 mg Apixaban Tablets are a prescription medication used primarily for the prevention of thromboembolic events, particularly in patients with atrial fibrillation (AF) and other conditions that increase the risk of blood clots. Apixaban, the active ingredient in these tablets, belongs to a class of drugs known as direct oral anticoagulants (DOACs). It works by inhibiting Factor Xa, an essential enzyme in the blood coagulation cascade, thereby preventing the formation of blood clots.
The medication is often prescribed to reduce the risk of stroke and systemic embolism in patients with non-valvular AF. Additionally, it is used for the treatment and prevention of deep vein thrombosis (DVT) and pulmonary embolism (PE) in certain patients. Its effectiveness in these areas makes it a valuable option for managing conditions associated with abnormal blood clotting.
Strengths of Apismart 2.5mg Tablets
What is Apismart 2.5mg Tablets Used For?
Apismart 2.5 mg Apixaban Tablets are used for several important medical indications:
- Prevention of Stroke and Systemic Embolism
- Treatment of Deep Vein Thrombosis (DVT)
- Prevention of Pulmonary Embolism (PE)
- Reduction of the Risk of Recurrence
- Management of Postoperative Thromboembolic Events
Manufacturer
Apismart 2.5 mg Apixaban Tablets are manufactured by Healing Pharma India Pvt Ltd, a pharmaceutical company based in India.
These tablets are anticoagulants, commonly prescribed to prevent and treat blood clots in conditions such as deep vein thrombosis (DVT) and pulmonary embolism (PE). They work by inhibiting Factor Xa, an essential enzyme in the blood coagulation cascade, thereby reducing the risk of stroke and systemic embolism.
How Does the Apismart 2.5mg Tablets Work?
Apismart 2.5 mg Apixaban Tablets work as an anticoagulant by directly inhibiting Factor Xa, an enzyme critical in the blood coagulation process. By blocking this enzyme, Apixaban prevents the conversion of prothrombin to thrombin, reducing the formation of fibrin and, consequently, the development of blood clots.
This mechanism helps lower the risk of thromboembolic events, such as strokes and systemic embolisms in patients with non-valvular atrial fibrillation, as well as in the treatment and prevention of deep vein thrombosis (DVT) and pulmonary embolism (PE). The rapid onset and predictable effects of Apixaban allow for effective management of these conditions without the need for routine blood monitoring.
Dosage
The usual recommended dosage of Apismart 2.5 mg Apixaban Tablets for adults is two tablets taken orally twice a day, totaling 5 mg daily. However, for patients with specific conditions, such as those who are at increased risk of bleeding or have certain renal impairments, a lower dose of 2.5 mg may be indicated.
Dosage adjustments may be necessary based on individual factors such as age, weight, kidney function, and the presence of other medical conditions. It is crucial for patients to follow their healthcare provider’s instructions regarding the dosage to ensure optimal effectiveness and minimize the risk of adverse effects.
Reviews
There are no reviews yet.